Yalian Machinery
001395
Beijing HyperStrong Technology
688411
Fuling Technology
001356
Hubei Sinophorus Electronic Materials
688545
Shantou Institute of Ultrasonic Instrument
301602
CN Stock MarketDetailed Quotes
300233 Shandong Jincheng Pharmaceutical Group
- 13.32
- 0.000.00%
Not Open Jan 24 09:30 CST
5.11BMarket Cap26.43P/E (TTM)
0.00High0.00Low0lotVolume0.00Open13.32Pre Close0.00Turnover0.00%Turnover Ratio29.27P/E (Static)383.87MShares20.2052wk High1.38P/B4.93BFloat Cap10.5352wk Low15.98Limit Up369.88MShs Float58.04Historical High10.66Limit Down0.00%Amplitude2.79Historical Low0.30Dividend TTM--Avg Price0lotAsk2.25%Div YieldTTM100Lot Size0lotBid
Shandong Jincheng Pharmaceutical Group Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -2.08%2.52B | 3.12%1.76B | 12.32%931.7M | 0.93%3.54B | -0.87%2.57B | -7.91%1.71B | -12.96%829.53M | 11.70%3.51B | 23.66%2.59B | 42.98%1.85B |
| Operating revenue | -2.08%2.52B | 3.12%1.76B | 12.32%931.7M | 0.93%3.54B | -0.87%2.57B | -7.91%1.71B | -12.96%829.53M | 11.70%3.51B | 23.66%2.59B | 42.98%1.85B |
| Other operating revenue | ---- | -5.58%8.64M | ---- | -17.72%17.66M | ---- | 25.88%9.15M | ---- | 82.12%21.46M | ---- | -7.98%7.27M |
| Total operating cost | -2.24%2.33B | 2.16%1.6B | 7.76%824.6M | 5.11%3.29B | 4.53%2.39B | -0.65%1.57B | -5.62%765.2M | 7.36%3.13B | 15.81%2.28B | 31.38%1.58B |
| Operating cost | 1.66%1.51B | 7.69%1.04B | 8.77%517.1M | 5.62%1.99B | 7.52%1.48B | -5.57%969.72M | -12.20%475.42M | 26.77%1.89B | 43.01%1.38B | 77.36%1.03B |
| Operating tax surcharges | 4.18%29.27M | 10.34%20.2M | 14.98%10.42M | 9.39%36.16M | 11.43%28.1M | 7.48%18.31M | -2.54%9.06M | 6.89%33.05M | 14.98%25.21M | 21.36%17.03M |
| Operating expense | -20.47%389.55M | -11.89%278.05M | 14.34%171.86M | 8.28%680.65M | 13.23%489.84M | 22.30%315.57M | 15.38%150.31M | -24.10%628.59M | -26.76%432.61M | -28.16%258.02M |
| Administration expense | 10.89%284.39M | -1.04%182.35M | -6.28%88.04M | -2.49%390.75M | -23.81%256.46M | -8.34%184.25M | 14.19%93.94M | 8.75%400.74M | 23.78%336.6M | 19.44%201.01M |
| Financial expense | -83.23%1.56M | -131.03%-2M | -106.80%-541.6K | -30.10%10.28M | 74.96%9.29M | 111.34%6.43M | 88.64%7.97M | -42.53%14.7M | -54.72%5.31M | -64.58%3.04M |
| -Interest expense (Financial expense) | -24.20%14.55M | -25.24%10.07M | -27.31%4.85M | -7.08%24.92M | 4.74%19.19M | 1.69%13.47M | 27.08%6.67M | -0.78%26.82M | -8.35%18.32M | 3.23%13.25M |
| -Interest Income (Financial expense) | -10.65%-10.45M | -23.59%-7.48M | -20.14%-4M | -19.07%-14.59M | -2.59%-9.44M | -1.38%-6.05M | -41.53%-3.33M | -1.80%-12.26M | 2.60%-9.2M | 12.89%-5.97M |
| Research and development | 0.60%122.56M | 7.05%81.58M | 32.32%37.72M | 7.95%184.71M | 14.87%121.82M | 2.03%76.2M | -34.08%28.5M | -4.06%171.1M | -5.38%106.05M | 0.80%74.69M |
| Credit Impairment Loss | 342.64%4.46M | 365.75%2.62M | 261.55%2.27M | -261.02%-4.81M | -124.55%-1.84M | 77.53%-987.39K | 66.99%-1.41M | -353.89%-1.33M | -29.14%7.49M | -132.80%-4.39M |
| Asset Impairment Loss | 45.20%-10.16M | 3.75%-7.2M | -32.16%-63.98K | -14.16%-46.54M | -1,639.85%-18.54M | -510.91%-7.48M | ---48.41K | 29.49%-40.77M | 42.56%1.2M | 38.51%1.82M |
| Other net revenue | 302.79%13.15M | 1,459.42%8.64M | 93.42%8.55M | -1.65%-18.8M | -120.86%-6.49M | -104.91%-635.82K | 53.63%4.42M | -89.51%-18.49M | -37.06%31.1M | -67.08%12.94M |
| Fair value change income | -2,174.82%-305.09K | 275.62%464.43K | 160.67%203.06K | 83.14%-81.54K | 94.64%-13.41K | -129.25%-264.45K | -139.67%-334.69K | 57.29%-483.57K | -104.64%-250.38K | -82.77%903.99K |
| Invest income | -2,066.29%-1.52M | -551.92%-2.17M | -902.57%-164.34K | -82.87%590.13K | -102.09%-70.37K | -129.65%-333.12K | -102.00%-16.39K | -72.45%3.44M | 156.30%3.37M | 268.89%1.12M |
| -Including: Investment income associates | -68.65%-411.24K | -206.80%-481.41K | -28.44%-315.69K | -55.02%-730.5K | 8.62%-243.84K | -282.71%-156.91K | -53.46%-245.79K | 45.99%-471.22K | 63.33%-266.85K | 91.05%-41K |
| Asset deal income | 159.75%1.56M | 148.25%1.37M | 146.28%173.42K | -241.37%-2.16M | -159.47%-2.61M | -165.26%-2.84M | -171.44%-374.73K | 48.96%1.53M | 532.85%4.39M | 440.66%4.35M |
| Other revenue | 15.27%19.12M | 20.27%13.56M | -7.09%6.13M | 78.84%34.2M | 11.35%16.59M | 23.50%11.27M | 33.38%6.6M | -45.59%19.12M | -51.30%14.9M | -49.92%9.13M |
| Operating profit | 11.25%195.27M | 21.31%162.77M | 68.22%115.65M | -36.16%225.85M | -48.22%175.52M | -52.76%134.17M | -52.64%68.75M | 68.43%353.78M | 95.62%338.94M | 116.37%284M |
| Add:Non operating Income | 181.23%2.18M | 114.10%1.55M | -89.00%71.93K | -82.61%983.97K | -69.99%773.54K | -52.08%725.99K | 55.19%654.02K | 288.29%5.66M | 201.65%2.58M | 105.79%1.52M |
| Less:Non operating expense | 4,450.00%500.16K | 141.12%325.77K | 119.97%166.74K | -89.42%1.43M | -100.09%-11.5K | -106.26%-792.18K | -161.88%-835.15K | -9.95%13.47M | 190.66%13.17M | 285.95%12.65M |
| Total profit | 11.71%196.94M | 20.86%164M | 64.52%115.55M | -34.85%225.41M | -46.31%176.3M | -50.27%135.69M | -51.30%70.24M | 76.02%345.97M | 93.61%328.35M | 111.99%272.87M |
| Less:Income tax cost | 17.52%34.84M | 0.47%25.04M | 71.88%26.4M | -46.59%32.1M | -51.60%29.65M | -48.79%24.92M | -45.49%15.36M | -18.21%60.09M | 53.78%61.26M | 59.52%48.66M |
| Net profit | 10.53%162.1M | 25.45%138.96M | 62.46%89.16M | -32.38%193.31M | -45.09%146.66M | -50.59%110.77M | -52.72%54.88M | 132.26%285.88M | 105.84%267.09M | 128.28%224.21M |
| Net profit from continuing operation | 10.53%162.1M | 25.45%138.96M | 62.46%89.16M | -32.38%193.31M | -45.09%146.66M | -50.59%110.77M | -52.72%54.88M | 132.26%285.88M | 105.84%267.09M | 128.28%224.21M |
| Less:Minority Profit | -22.07%11.05M | -7.64%8.37M | 30.95%6.19M | 48.70%18.6M | 63.02%14.17M | 73.09%9.06M | 31.70%4.73M | -17.15%12.51M | -7.67%8.69M | 0.52%5.24M |
| Net profit of parent company owners | 14.02%151.05M | 28.40%130.59M | 65.43%82.97M | -36.09%174.71M | -48.73%132.48M | -53.55%101.71M | -55.41%50.15M | 153.15%273.37M | 114.72%258.39M | 135.44%218.97M |
| Earning per share | ||||||||||
| Basic earning per share | 17.65%0.4 | 30.77%0.34 | 69.23%0.22 | -36.62%0.45 | -49.25%0.34 | -54.39%0.26 | -55.17%0.13 | 153.57%0.71 | 116.13%0.67 | 137.50%0.57 |
| Diluted earning per share | 17.65%0.4 | 30.77%0.34 | 69.23%0.22 | -36.62%0.45 | -49.25%0.34 | -54.39%0.26 | -55.17%0.13 | 153.57%0.71 | 116.13%0.67 | 137.50%0.57 |
| Other composite income | 1.71M | 7.06M | 7.06M | 5.51M | ||||||
| Other composite income of parent company owners | ---- | ---- | ---- | --1.71M | --7.06M | --7.06M | --5.51M | ---- | ---- | ---- |
| Total composite income | 5.46%162.1M | 17.94%138.96M | 47.64%89.16M | -31.78%195.02M | -42.45%153.71M | -47.45%117.83M | -47.97%60.39M | 122.77%285.88M | 97.85%267.09M | 128.28%224.21M |
| Total composite income of parent company owners | 8.25%151.05M | 20.07%130.59M | 49.05%82.97M | -35.47%176.41M | -46.00%139.54M | -50.33%108.77M | -50.51%55.67M | 141.43%273.37M | 105.76%258.39M | 135.44%218.97M |
| Total composite income of minority owners | -22.07%11.05M | -7.64%8.37M | 30.95%6.19M | 48.70%18.6M | 63.02%14.17M | 73.09%9.06M | 31.70%4.73M | -17.15%12.51M | -7.67%8.69M | 0.52%5.24M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- | -- | Shanghui Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
